Physician profile
Andreas D Rotsides
NPI 1295799153
$7,308.63
in general payments reported to CMS, 2019-2025
37 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $1,043 · 2021: $1,062 · 2022: $1,136 · 2023: $1,054 · 2024: $951 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,494.97 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,649.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,318.38 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,016.49 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $705.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Corcept Therapeutics | $306.10 | 2024-2025 | Korlym |
| Pfizer INC. | $247.18 | 2020-2025 | |
| Lilly USA, LLC | $217.21 | 2019-2025 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $196.84 | 2020-2023 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $181.28 | 2020-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.47 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $114.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $111.53 | 2019-2021 | |
| Amarin Pharma, INC. | $98.52 | 2021-2023 | |
| Astellas Pharma US INC | $96.16 | 2019-2021 | |
| Allergan, INC. | $92.42 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Rotsides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.